Abstract
Emesis is a common side effect of some antineoplastic drugs. Cisplatin (CP) induces a biphasic pattern of emesis referred to as acute (AE) and delayed (DE) emesis. The serotonergic system plays a major role in the pathogenesis of CP-induced AE, as suggested by the therapeutic efficacy of 5HT3 receptor antagonists. The pathogenesis of CP-induced DE are not clear. To date, there are no pharmacological agents which satisfactorily control DE. We hypothesize that increased availability of tryptophan (TRP) for the synthesis of brain serotonin (5-HT) could, at least in part, contribute to CP-induced DE. In fact, within 2-4 hrs of administration, CP is largely bound to albumin (ALB) with consequent possible displacement of TRP which circulates in plasma mostly (90% of total plasma TRP) bound to its natural carrier, ALB. To test this hypothesis, we studied in vitro the effect of increasing doses of cisplatin on F-TRP in plasma obtained from healthy volunteers. We also tested the effects of therapeutic amounts of paclitaxel, an antineoplastc agent which does not cause emesis. Results: F-TRP concentrations increased in a dose-dependent manner following incubation with cisplatin, in contrast to paclitaxel (PTX). Conclusions: The preliminary data obtained suggest that CP, but not PTX, at therapeutic doses, increases plasma F-TRP concentrations. This increase has likely negligible relevance in CP-induced AE, which is induced by the 5-HT released by the enterochromaffin cell system, while it might play a role in the pathogenesis of CP-induced DE. In fact, CP binding to ALB is stable for 4-5 days following administration, thus suggesting long-term TRP displacement from ALB and enhanced brain 5-HT synthesis and release. Whether increased TRP availability for 5-HT synthesis might be the pathogenic mechanism for CP-induced DE in vivo, is currently being tested.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bloxam D.L. and Warren W.H., 1971, Error in the determination of triptophan by the method of Denckla and Dewey. A revised procedure. Ann. Biochem. 60:0621–625.
Cubeddu L.X., 1996, Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology. 53(Suppl 1):18–25.
Fischer, D.S., Tish Knobf, M., and Durivage, H.J., 1993, Cisplatin, in: The Cancer Chemotherapy Handbook, Fourth Edition, pp 116–121, Masson Milan Italy.
Hesketh P., 1996, Management of cisplatin-induced emesis. Oncology. 53:(Suppl) 1:73–29.
Matsui K., Fukuoka M., Takada M., Kusunoki Y., Yana T., Tamura K., Yoshida T., Iida K., Hirashima T., Tsukada H., Ushijima S., Miyawaki H., and Masuda N., 1996, Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Brit. J. Canc. 73:217–221.
Muscaritoli M., Meguid M.M., Beverly J.L., Yang Z.J., Cangiano C., and Rossi Fanelli F., 1996, The early anorexia paradigm. J. Surg. Res. 60:338–397.
Naylor R.J. and Rudd J.A., 1996, Mechanisms of Chemotherapy/Radiotherapy-Induced Emesis in Animal models. Oncology. 53(Suppl 1):8–17.
Rossi Fanelli F., Cangiano C., Ceci F., Cellerino R., Franchi F., Menichetti E.T., Muscaritoli M., and Cascino A., 1986, Plasma Tryptophan and Anorexia in Human Cancer. Eur J Cancer Clin Oncol. 22:89–95.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Muscaritoli, M. et al. (1999). Effect of Cisplatin and Paclitaxel on Plasma Free Tryptophan Levels. In: Huether, G., Kochen, W., Simat, T.J., Steinhart, H. (eds) Tryptophan, Serotonin, and Melatonin. Advances in Experimental Medicine and Biology, vol 467. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4709-9_34
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4709-9_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7133-5
Online ISBN: 978-1-4615-4709-9
eBook Packages: Springer Book Archive